Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
NCT ID: NCT01485887
Last Updated: 2021-01-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
50 participants
INTERVENTIONAL
2012-01-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
NCT01441440
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
NCT00087737
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
NCT00448058
Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
NCT00090649
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
NCT00247429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Venlafaxine ER
Venlafaxine ER
Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venlafaxine ER
Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Significant risk of suicide based on clinical judgment.
* Use of prohibited treatments
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nippon Medical School Chiba Hokusoh Hospital
Inzai, Chiba, Japan
Nakamoto Clinic
Noda, Chiba, Japan
Stress Care Yoshimura Clinic
Fukuoka, Fukuoka, Japan
Hatakeyama Clinic
Kitakyushu, Fukuoka, Japan
Shiranui Hospital
Omuta, Fukuoka, Japan
Fujikawa Clinic
Hatsukaichi, Hiroshima, Japan
Takahashi Psychiatric Clinic
Ashiya, Hyōgo, Japan
Ikeuchi Psycho Induced Internal Med.Clinic
Kobe, Hyōgo, Japan
National Hospital Organization Kanazawa Medical Center
Kanazawa, Ishikawa-ken, Japan
Medical Corporation Seishinkai Kishiro Mental Clinic
Kawasaki, Kanagawa, Japan
Yutaka Clinic
Sagamihara-shi, Kanagawa, Japan
Tawara Clinic
Yokohama, Kanagawa, Japan
Shioiri Mental Clinic
Yokosuka, Kanagawa, Japan
Shibamoto Clinic
Osakasayama-shi, Osaka, Japan
Suzuki Hospital
Adachi-ku, Tokyo, Japan
Sangenjaya Nakamura Mental Clinic
Setagaya-ku, Tokyo, Japan
Omotesando Mental Clinic
Shibuya-ku, Tokyo, Japan
Maynds Tower Mental Clinic
Shibuya-ku, Tokyo, Japan
Tokyo Kosei Nenkin Hospital
Shinjuku-ku, Tokyo, Japan
Himorogi Psychiatric Institute
Toshima-ku, Tokyo, Japan
Tenjin Mental Clinic
Fukuoka, , Japan
Stress Care Yoshimura Clinic
Fukuoka, , Japan
Kuranari Psychiatry Clinic
Fukuoka, , Japan
Medical Corporation Toyokokai Tawara Clinic
Kanagawa, , Japan
Sagaarashiyama-Tanaka Clinic
Kyoto, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Higuchi T, Kamijima K, Nakagome K, Itamura R, Asami Y, Kuribayashi K, Imaeda T. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. Int Clin Psychopharmacol. 2016 Jan;31(1):8-19. doi: 10.1097/YIC.0000000000000105.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2411264
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.